vs
Hippo Holdings Inc.（HIPO）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
Hippo Holdings Inc.的季度营收约是RIGEL PHARMACEUTICALS INC的1.7倍（$120.4M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 5.0%，领先379.1%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 18.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 18.9%）
河马谷庄园是一座甘蔗种植园，坐落于津巴布韦东南部奇雷济区奇雷济镇附近，位于伦迪河沿岸，毗邻莫桑比克边境，是当地重要的蔗糖产业园区。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
HIPO vs RIGL — 直观对比
营收规模更大
HIPO
是对方的1.7倍
$69.8M
营收增速更快
RIGL
高出3.0%
18.2%
净利率更高
RIGL
高出379.1%
5.0%
两年增速更快
RIGL
近两年复合增速
18.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $120.4M | $69.8M |
| 净利润 | $6.0M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 5.6% | 33.2% |
| 净利率 | 5.0% | 384.0% |
| 营收同比 | 18.2% | 21.2% |
| 净利润同比 | -86.4% | 1769.2% |
| 每股收益（稀释后） | $0.31 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HIPORIGL
| Q4 25 | $120.4M | $69.8M | ||
| Q3 25 | $120.6M | $69.5M | ||
| Q2 25 | $117.3M | $101.7M | ||
| Q1 25 | $110.3M | $53.3M | ||
| Q4 24 | $101.9M | $57.6M | ||
| Q3 24 | $95.5M | $55.3M | ||
| Q2 24 | $89.6M | $36.8M | ||
| Q1 24 | $85.1M | $29.5M |
净利润HIPORIGL
| Q4 25 | $6.0M | $268.1M | ||
| Q3 25 | $98.1M | $27.9M | ||
| Q2 25 | $1.3M | $59.6M | ||
| Q1 25 | $-47.7M | $11.4M | ||
| Q4 24 | $44.2M | $14.3M | ||
| Q3 24 | $-8.5M | $12.4M | ||
| Q2 24 | $-40.5M | $-1.0M | ||
| Q1 24 | $-35.7M | $-8.2M |
毛利率HIPORIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率HIPORIGL
| Q4 25 | 5.6% | 33.2% | ||
| Q3 25 | 81.3% | 40.9% | ||
| Q2 25 | 3.4% | 60.1% | ||
| Q1 25 | -41.3% | 23.9% | ||
| Q4 24 | 46.3% | 28.9% | ||
| Q3 24 | -5.4% | 25.4% | ||
| Q2 24 | -40.7% | 1.2% | ||
| Q1 24 | -38.7% | -23.6% |
净利率HIPORIGL
| Q4 25 | 5.0% | 384.0% | ||
| Q3 25 | 81.3% | 40.2% | ||
| Q2 25 | 1.1% | 58.6% | ||
| Q1 25 | -43.2% | 21.5% | ||
| Q4 24 | 43.4% | 24.9% | ||
| Q3 24 | -8.9% | 22.5% | ||
| Q2 24 | -45.2% | -2.8% | ||
| Q1 24 | -42.0% | -27.9% |
每股收益（稀释后）HIPORIGL
| Q4 25 | $0.31 | $14.11 | ||
| Q3 25 | $3.77 | $1.46 | ||
| Q2 25 | $0.05 | $3.28 | ||
| Q1 25 | $-1.91 | $0.63 | ||
| Q4 24 | $1.81 | $0.82 | ||
| Q3 24 | $-0.34 | $0.70 | ||
| Q2 24 | $-1.64 | $-0.06 | ||
| Q1 24 | $-1.47 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $218.3M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $436.1M | $391.5M |
| 总资产 | $1.9B | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资HIPORIGL
| Q4 25 | $218.3M | $155.0M | ||
| Q3 25 | $247.7M | $137.1M | ||
| Q2 25 | $198.9M | $108.4M | ||
| Q1 25 | $140.9M | $77.1M | ||
| Q4 24 | $197.6M | $77.3M | ||
| Q3 24 | $191.2M | $61.1M | ||
| Q2 24 | $175.9M | $49.1M | ||
| Q1 24 | $223.4M | $49.5M |
总债务HIPORIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益HIPORIGL
| Q4 25 | $436.1M | $391.5M | ||
| Q3 25 | $421.5M | $117.6M | ||
| Q2 25 | $332.5M | $81.9M | ||
| Q1 25 | $322.8M | $18.6M | ||
| Q4 24 | $362.1M | $3.3M | ||
| Q3 24 | $326.4M | $-14.6M | ||
| Q2 24 | $322.6M | $-29.9M | ||
| Q1 24 | $351.2M | $-31.7M |
总资产HIPORIGL
| Q4 25 | $1.9B | $513.6M | ||
| Q3 25 | $1.9B | $242.5M | ||
| Q2 25 | $1.7B | $206.7M | ||
| Q1 25 | $1.5B | $176.0M | ||
| Q4 24 | $1.5B | $164.0M | ||
| Q3 24 | $1.5B | $139.4M | ||
| Q2 24 | $1.5B | $128.4M | ||
| Q1 24 | $1.5B | $126.5M |
负债/权益比HIPORIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.2M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $9.1M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | 1.53× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $14.8M | — |
8季度趋势，按日历期对齐
经营现金流HIPORIGL
| Q4 25 | $9.2M | $22.0M | ||
| Q3 25 | $16.9M | $24.0M | ||
| Q2 25 | $24.7M | $30.5M | ||
| Q1 25 | $-35.6M | $-893.0K | ||
| Q4 24 | $47.5M | $14.5M | ||
| Q3 24 | $46.8M | $21.7M | ||
| Q2 24 | $-10.6M | $302.0K | ||
| Q1 24 | $17.7M | $-5.0M |
自由现金流HIPORIGL
| Q4 25 | $9.1M | — | ||
| Q3 25 | $16.8M | — | ||
| Q2 25 | $24.6M | — | ||
| Q1 25 | $-35.7M | — | ||
| Q4 24 | $47.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-10.7M | — | ||
| Q1 24 | $17.6M | — |
自由现金流率HIPORIGL
| Q4 25 | 7.6% | — | ||
| Q3 25 | 13.9% | — | ||
| Q2 25 | 21.0% | — | ||
| Q1 25 | -32.4% | — | ||
| Q4 24 | 46.3% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -11.9% | — | ||
| Q1 24 | 20.7% | — |
资本支出强度HIPORIGL
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
现金转化率HIPORIGL
| Q4 25 | 1.53× | 0.08× | ||
| Q3 25 | 0.17× | 0.86× | ||
| Q2 25 | 19.00× | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | 1.07× | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
